Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01947608
Expanded Access Status : No longer available
First Posted : September 20, 2013
Last Update Posted : November 3, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Tracking Information
First Submitted Date September 17, 2013
First Posted Date September 20, 2013
Last Update Posted Date November 3, 2020
 
Descriptive Information
Brief Title Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Brief Summary Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: LDK378
750 mg. orally
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Argentina,   Colombia,   Hong Kong,   India,   Jordan,   Korea, Republic of,   Mexico,   Philippines,   Thailand,   United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01947608
Responsible Party Novartis ( Novartis Pharmaceuticals )
Study Sponsor Novartis Pharmaceuticals
Collaborators Not Provided
Investigators Not Provided
PRS Account Novartis
Verification Date December 2019